JPH0446928B2 - - Google Patents

Info

Publication number: JPH0446928B2
Authority: JP; Japan
Prior art keywords: lymphotoxin; cells; human; animal; derived
Prior art date: 1981-07-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP56112914A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5815921A (ja

Inventor

Haruo Oonishi

Masakazu Mihashi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hayashibara Seibutsu Kagaku Kenkyujo KK

Mochida Pharmaceutical Co Ltd

Original Assignee

Hayashibara Seibutsu Kagaku Kenkyujo KK

Mochida Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-07-21

Filing date

1981-07-21

Publication date

1992-07-31

1981-07-21 Application filed by Hayashibara Seibutsu Kagaku Kenkyujo KK, Mochida Pharmaceutical Co Ltd filed Critical Hayashibara Seibutsu Kagaku Kenkyujo KK

1981-07-21 Priority to JP56112914A priority Critical patent/JPS5815921A/ja

1982-07-19 Priority to FR8212541A priority patent/FR2513124B1/fr

1982-07-19 Priority to SE8204382A priority patent/SE8204382L/xx

1982-07-20 Priority to IT48855/82A priority patent/IT1196549B/it

1982-07-20 Priority to AU86200/82A priority patent/AU560793B2/en

1982-07-20 Priority to CH4420/82A priority patent/CH664974A5/fr

1982-07-20 Priority to KR8203215A priority patent/KR870001433B1/ko

1982-07-21 Priority to US06/400,487 priority patent/US4495282A/en

1982-07-21 Priority to DE3227262A priority patent/DE3227262C3/de

1982-07-21 Priority to GB08221100A priority patent/GB2106117B/en

1982-07-21 Priority to DE3249946A priority patent/DE3249946C2/de

1982-07-21 Priority to ES514210A priority patent/ES514210A0/es

1982-07-21 Priority to AT0283582A priority patent/AT387980B/de

1983-01-29 Publication of JPS5815921A publication Critical patent/JPS5815921A/ja

1990-02-14 Priority to SE9000532A priority patent/SE9000532L/xx

1992-07-31 Publication of JPH0446928B2 publication Critical patent/JPH0446928B2/ja

Status Granted legal-status Critical Current

Links

102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 75
108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 75
241001465754 Metazoa Species 0.000 claims description 37
238000000338 in vitro Methods 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 8
210000001124 body fluid Anatomy 0.000 claims description 6
239000010839 body fluid Substances 0.000 claims description 6
241000282412 Homo Species 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 3
239000000411 inducer Substances 0.000 claims description 3
210000004027 cell Anatomy 0.000 description 73
238000004519 manufacturing process Methods 0.000 description 18
238000000034 method Methods 0.000 description 11
206010028980 Neoplasm Diseases 0.000 description 9
235000015097 nutrients Nutrition 0.000 description 8
230000000694 effects Effects 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
201000011510 cancer Diseases 0.000 description 6
239000002609 medium Substances 0.000 description 6
230000035755 proliferation Effects 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
238000009792 diffusion process Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 5
238000011580 nude mouse model Methods 0.000 description 5
239000002504 physiological saline solution Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
206010006187 Breast cancer Diseases 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 4
241000699660 Mus musculus Species 0.000 description 4
108010047620 Phytohemagglutinins Proteins 0.000 description 4
239000003889 eye drop Substances 0.000 description 4
229940012356 eye drops Drugs 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000002674 ointment Substances 0.000 description 4
230000001885 phytohemagglutinin Effects 0.000 description 4
239000000843 powder Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000003826 tablet Substances 0.000 description 4
238000002054 transplantation Methods 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
206010003445 Ascites Diseases 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
201000007270 liver cancer Diseases 0.000 description 3
208000014018 liver neoplasm Diseases 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
208000000453 Skin Neoplasms Diseases 0.000 description 2
210000000683 abdominal cavity Anatomy 0.000 description 2
230000007059 acute toxicity Effects 0.000 description 2
231100000403 acute toxicity Toxicity 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
244000309466 calf Species 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000012258 culturing Methods 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
239000002662 enteric coated tablet Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
230000009036 growth inhibition Effects 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000028993 immune response Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000000746 purification Methods 0.000 description 2
201000000849 skin cancer Diseases 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
102000016605 B-Cell Activating Factor Human genes 0.000 description 1
108010028006 B-Cell Activating Factor Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
241000272201 Columbiformes Species 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000711408 Murine respirovirus Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000005273 aeration Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
238000003163 cell fusion method Methods 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000009422 growth inhibiting effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
108010086662 phytohemagglutinin-M Proteins 0.000 description 1
108010086652 phytohemagglutinin-P Proteins 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000006798 recombination Effects 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000005185 salting out Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
241000894007 species Species 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

JP56112914A 1981-07-21 1981-07-21 抗リンホトキシン感受性疾患剤 Granted JPS5815921A (ja)

Priority Applications (14)

Application Number	Priority Date	Filing Date	Title
JP56112914A JPS5815921A (ja)	1981-07-21	1981-07-21	抗リンホトキシン感受性疾患剤
FR8212541A FR2513124B1 (fr)	1981-07-21	1982-07-19	Production et applications du facteur de lyse des cellules-cibles
SE8204382A SE8204382L (sv)	1981-07-21	1982-07-19	Sett att framstella malcellysfaktor och anvendning derav
IT48855/82A IT1196549B (it)	1981-07-21	1982-07-20	Procedimento per la produzione del fattore di lisi cellule bersaglio (tclf),prodotto ottenuto a suo impiego in terapia clinica,in particolare come agente citolitico antitumurale
AU86200/82A AU560793B2 (en)	1981-07-21	1982-07-20	Production of target cell lysis factor
CH4420/82A CH664974A5 (fr)	1981-07-21	1982-07-20	Production du facteur de lyse des cellules-cibles.
KR8203215A KR870001433B1 (ko)	1981-07-21	1982-07-20	적상적혈구(的狀赤血球) 붕괴인자의 제조 방법
US06/400,487 US4495282A (en)	1981-07-21	1982-07-21	Process for producing target cell lysis factor and uses therewith
DE3227262A DE3227262C3 (de)	1981-07-21	1982-07-21	Verfahren zur Herstellung von menschlichem Tumor-Nekrose-Faktor und menschlicher Tumor-Nekrose-Faktor
GB08221100A GB2106117B (en)	1981-07-21	1982-07-21	Process for producing target cell lysis factor
DE3249946A DE3249946C2 (de)	1981-07-21	1982-07-21	hTNF-haltiges therapeutisches Mittel gegen maligne Tumoren und dessen Verwendung
ES514210A ES514210A0 (es)	1981-07-21	1982-07-21	Un procedimiento para la produccion de tclf.
AT0283582A AT387980B (de)	1981-07-21	1982-07-21	Verfahren zur herstellung eines die aufloesung menschlicher zellen bewirkenden faktors
SE9000532A SE9000532L (sv)	1981-07-21	1990-02-14	Farmaceutisk tclf-komposition

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP56112914A JPS5815921A (ja)	1981-07-21	1981-07-21	抗リンホトキシン感受性疾患剤

Publications (2)

Publication Number	Publication Date
JPS5815921A JPS5815921A (ja)	1983-01-29
JPH0446928B2 true JPH0446928B2 (it)	1992-07-31

Family

ID=14598641

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP56112914A Granted JPS5815921A (ja)	1981-07-21	1981-07-21	抗リンホトキシン感受性疾患剤

Country Status (1)

Country	Link
JP (1)	JPS5815921A (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5889195A (ja) *	1981-11-21	1983-05-27	Hayashibara Biochem Lab Inc	標的細胞障害性因子の製造方法
JPH0764744B2 (ja) *	1981-11-21	1995-07-12	株式会社林原生物化学研究所	標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤

1981
- 1981-07-21 JP JP56112914A patent/JPS5815921A/ja active Granted

Also Published As

Publication number	Publication date
JPS5815921A (ja)	1983-01-29

Publication	Publication Date	Title
NL192086C (nl)	1997-02-04	Werkwijze ter bereiding van interferonen en werkwijze ter bereiding van een geneesmiddel dat interferonen bevat.
US4495282A (en)	1985-01-22	Process for producing target cell lysis factor and uses therewith
US4621050A (en)	1986-11-04	Process for the production of human colony-stimulating factor
JPS631296B2 (it)	1988-01-12
KR930000188B1 (ko)	1993-01-11	신규 림포카인(lymphokine), 이 림포카인에 특이적인 모노클로날 항체 및 이들의 제조방법
JPS6227048B2 (it)	1987-06-12
KR930004596B1 (ko)	1993-06-01	신규 림포킨(lymphokine) 및 이에 대해 특이성을 갖는 모노클로날(monoclonal) 항체의 제조 방법
JPS58107197A (ja)	1983-06-25	ツモアネクロシスフアクタ−の製造方法
JPH0446928B2 (it)	1992-07-31
JPH0214039B2 (it)	1990-04-05
JPS5821621A (ja)	1983-02-08	ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
KR950008569B1 (ko)	1995-08-03	신규 림포카인(lymphokine) 및 그 제조방법과 사용방법
JPS5888322A (ja)	1983-05-26	標的細胞障害性因子を含有する悪性腫瘍治療剤とその製造方法
JP2926409B2 (ja)	1999-07-28	癌転移抑制因子の製造方法
JP2532025B2 (ja)	1996-09-11	新リンホカインｉｉｉを有効成分とする抗腫瘍作用を有するリンホカインの活性増強剤
KR970002165B1 (ko)	1997-02-24	γ-인터페론의 제조방법과 그 용도
JP2518634B2 (ja)	1996-07-24	ヒトツモア・ネクロシス・フアクタ−の製造方法
JP2518635B2 (ja)	1996-07-24	ヒトツモア・ネクロシス・フアクタ−
JP2850293B2 (ja)	1999-01-27	γ−インターフェロン感受性疾患剤
KR820001174B1 (ko)	1982-06-29	사람 특이성 인터페론의 제조법
KR830001817B1 (ko)	1983-09-12	타이프ⅱ 인터페론의 제조방법
JPH0527640B2 (it)	1993-04-21
JPH0523755B2 (it)	1993-04-05
JPS61115027A (ja)	1986-06-02	新リンホカイン２とその製法および用途
JPS5889195A (ja)	1983-05-27	標的細胞障害性因子の製造方法